Form 483

Hisun Pharmaceutical (Hangzhou) Co., Ltd. Form 483, 2016-05-20

FDA issued a Form 483 to Hisun Pharmaceutical (Hangzhou) Co., Ltd. on 2016-05-20 with 9 public-safe observations.

483· Form 483 issuedHuman Drugs9 observations

Hisun Pharmaceutical (Hangzhou) Co., Ltd. · Hangzhou, China · Issued May 20, 2016

Overview

  • 9 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

20 May 2016
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Toyin B Oladimeji

20 May 2016
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Toyin B Oladimeji

20 May 2016
21 CFR 211.166(a)

Written program not followed

Cited by Toyin B Oladimeji

20 May 2016
21 CFR 211.166(a)

Written program not followed

Cited by Toyin B Oladimeji

20 May 2016
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Toyin B Oladimeji

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations3x
21 CFR 211.166(a)Cited across public-safe Form 483 observations3x
21 CFR 211.67(b)Cited across public-safe Form 483 observations3x

Full 483 report

Get the verbatim text of all 9 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere